Physician profile
Kristen Foering
NPI 1437444288
$4,916.97
in general payments reported to CMS, 2019-2025
26 companies · $23.60 in 2025
The $23.60 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $988 · 2020: $367 · 2021: $246 · 2022: $421 · 2023: $1,414 · 2024: $1,457 · 2025: $23.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,712 · Education: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,712.02 |
| Education | $182.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,502.47 | 2019-2024 | Tremfya, Simponi Aria, Simponi |
| Abbvie INC. | $579.11 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $522.05 | 2019-2024 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $390.65 | 2023-2024 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $294.04 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $222.51 | 2022-2024 | Ilumya, Absorica Ld, Winlevi |
| Lilly USA, LLC | $217.05 | 2019-2024 | Taltz, Olumiant, Zepbound |
| Leo Pharma INC. | $196.46 | 2019-2024 | Adbry |
| Vyne Pharmaceuticals INC. | $133.53 | 2020-2021 | |
| Genzyme Corporation | $94.17 | 2023-2024 | |
| Pfizer INC. | $89.32 | 2024 | |
| Amgen INC. | $88.77 | 2020-2024 | Otezla |
| Arcutis Biotherapeutics, INC. | $85.12 | 2023-2024 | Zoryve |
| Ucb, INC. | $81.93 | 2019-2024 | Bimzelx |
| Sanofi-Aventis U.S. LLC | $72.00 | 2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $56.55 | 2019 | |
| Dermavant Sciences, INC. | $50.23 | 2024 | Vtama |
| Incyte Corporation | $49.92 | 2023 | Opzelura |
| Verrica Pharmaceuticals INC. | $34.60 | 2024 | Ycanth |
| Galderma Laboratories, L.P. | $31.72 | 2024 | Aklief |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $31.71 | 2019-2020 | |
| Helsinn Therapeutics (U.S.), INC. | $29.54 | 2023 | Valchlor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.76 | 2023 | Spevigo |
| Almirall LLC | $18.51 | 2020 | |
| Promius Pharma LLC | $12.43 | 2019 | |
| Encore Dermatology INC. | $10.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristen Foering listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.